Daniel Wiseman

Mr. Daniel Wiseman

Aston University, Birmingham, B4 7ET, United Kingdom
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Protein Expression and Purification
Verified
Journal Article
Open access
DWDaniel Wiseman
Daniel Wiseman
AOAbigail Otchere
Abigail Otchere
JPJaimin H. Patel
Jaimin H. Patel
RURomez Uddin
Romez Uddin
NPNaomi L. Pollock
Naomi L. Pollock
Alan GoddardAlan Goddard
Alan Goddard
Given their extensive role in cell signalling, GPCRs are significant drug targets; despite this, many of these receptors have limited or no available prophylaxis. Novel drug design and discovery significantly rely on structure determination, of which GPCRs are typically elusive. Progress has been made thus far to produce sufficient quantity and quality of protein for downstream analysis. As such, this review highlights the systems available for recombinant GPCR expression, with consideration of their advantages and disadvantages, as well as examples of receptors successfully expressed in these systems. Additionally, an overview is given on the use of detergents and the styrene maleic acid (SMA) co-polymer for membrane solubilisation, as well as purification techniques.

1 September 2018 in Methods
Verified
Journal Article
Closed access
OCOliver K. Castell
Oliver K. Castell
PDPatricia M. Dijkman
Patricia M. Dijkman
DWDaniel Wiseman
Daniel Wiseman
Alan GoddardAlan Goddard
Alan Goddard

23 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DWDaniel Wiseman
Daniel Wiseman
NSNikita Samra
Nikita Samra
MLMaría Monserrat Román Lara
María Monserrat Román Lara
SPSamantha Penrice
Samantha Penrice
Alan GoddardAlan Goddard
Alan Goddard
The G protein-coupled receptor (GPCR) superfamily is a large group of membrane proteins which, because of their vast involvement in cell signalling pathways, are implicated in a plethora of disease states and are therefore considered to be key drug targets. Despite advances in techniques to study these receptors, current prophylaxis is often limited due to the challenging nature of their dynamic, complex structures. Greater knowledge and understanding of their intricate structural rearrangements will therefore undoubtedly aid structure-based drug design against GPCRs. Disciplines such as anthropology and palaeontology often use geometric morphometrics to measure variation between shapes and we have therefore applied this technique to analyse GPCR structures in a three-dimensional manner, using principal component analysis. Our aim was to create a novel system able to discriminate between GPCR structures and discover variation between them, correlated with a variety of receptor characteristics. This was conducted by assessing shape changes at the extra- and intracellular faces of the transmembrane helix bundle, analysing the XYZ coordinates of the amino acids at those positions. We have demonstrated that GPCR structures can be classified based on characteristics such as activation state, bound ligands and fusion proteins, with the most significant results focussed at the intracellular face. Conversely, our analyses provide evidence that thermostabilising mutations do not cause significant differences when compared to non-mutated GPCRs. We believe that this is the first time geometric morphometrics has been applied to membrane proteins on this scale, and believe it can be used as a future tool in sense-checking newly resolved structures and planning experimental design.